Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fatty acids and schizophrenia

J D Laugharne1, J E Mellor, M Peet

  • 1University Department of Psychiatry, Northern General Hospital, Sheffield, United Kingdom.

Lipids
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple cerebral infarction associated with neuroleptic-induced lupus anticoagulant.

Behavioural neurology·2014
Same author

Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Commentary on 'The management of treatment-resistant affective disorder: clinical perspectives'.

Journal of psychopharmacology (Oxford, England)·2012
Same author

The ratio of plasma phenylalanine to other large neutral amino acids is not a risk factor for tardive dyskinesia.

Journal of psychopharmacology (Oxford, England)·2012
Same author

The prevention of suicide in patients with recurrent mood disorder.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Antidepressant drug treatment in relation to the use of ECT.

Journal of psychopharmacology (Oxford, England)·2012
Same journal

Oral Delivery of Tocotrienols: Addressing Pharmacokinetic Challenges With Formulation-Based Strategies.

Lipids·2026
Same journal

Very Low Cholesterol Non-Cardiovascular Risks: A Critical Appraisal and Framework for Individualized Management.

Lipids·2026
Same journal

Exometabolomics Reveals Metabolic Modulation Induced by Chia Oil Supplementation in Adipose Tissue Explants From Obese Mice.

Lipids·2026
Same journal

Analysis of the Value of Combined Detection of Serum miR-302a-3p and Low Density Lipoprotein Cholesterol in the Diagnosis of Coronary Heart Disease.

Lipids·2026
Same journal

Association Between C-Reactive Protein-Triglyceride Glucose Index, and the Risk of Osteoarthritis and Rheumatoid Arthritis: Results From NHANES 1999-2010.

Lipids·2026
Same journal

Transcriptomic Analysis of Shared Lipid Metabolism in Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease Using Weighted Gene Expression Network Analysis.

Lipids·2026
See all related articles

Patients with schizophrenia show depleted n-3 and n-6 fatty acids. Fish oil supplementation improved symptoms, suggesting dietary fatty acids are key for managing schizophrenia.

Area of Science:

  • Neuroscience
  • Nutritional Psychiatry

Background:

  • Schizophrenia is linked to altered red cell membrane fatty acids, particularly n-3 and n-6 series.
  • Specific fatty acids like arachidonic acid and docosahexaenoic acid are notably depleted in patients.

Purpose of the Study:

  • To investigate the role of fatty acid abnormalities in schizophrenia.
  • To assess the therapeutic potential of dietary fatty acid supplementation in schizophrenia patients.

Main Methods:

  • Controlled study analyzing red cell membrane fatty acids in schizophrenia patients.
  • Dietary analysis to assess fatty acid intake.
  • Six-week dietary supplementation with fish oil (MaxEPA) in patients.

Main Results:

  • Significant depletions of n-3 and n-6 fatty acids were observed in patients.

Related Experiment Videos

  • Higher n-3 fatty acid intake correlated with less severe schizophrenia symptoms.
  • Fish oil supplementation led to clinical improvement, linked to increased red cell membrane n-3 levels.

    • Conclusions:

    • Evidence suggests cell membrane fatty acid abnormalities in schizophrenia.
    • Dietary manipulation, specifically n-3 fatty acid supplementation, shows therapeutic promise for schizophrenia.
    • Further research into fatty acid metabolism and supplementation is warranted.